- Conditions
- SARS-CoV-2
- Interventions
- REGN14256, imdevimab, casirivimab + imdevimab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 28
- States / cities
- La Mesa, California • Long Beach, California • Mission Viejo, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COVID-19
- Interventions
- REGN10933+REGN10987 combination therapy, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 57
- States / cities
- Mesa, Arizona • Tucson, Arizona • Canoga Park, California + 48 more
- Conditions
- Healthy, Chronic Stable Illness
- Interventions
- REGN10933+REGN10987, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 974 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Tempe, Arizona • Rogers, Arkansas • Sacramento, California + 4 more
- Conditions
- Coronavirus, Covid19
- Interventions
- bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,044 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 207
- States / cities
- Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more
- Conditions
- Healthy Participants
- Interventions
- REGN10933 + REGN10987, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 1 Day and older
- Enrollment
- 3,303 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 132
- States / cities
- Mesa, Arizona • Tucson, Arizona • La Mesa, California + 94 more
- Conditions
- Healthy, Chronic Stable Illness
- Interventions
- Casirivimab+Imdevimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Miami, Florida • Winter Park, Florida
- Conditions
- COVID-19
- Interventions
- casirivimab+imdevimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 1 Minute to 17 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Stony Brook, New York • Memphis, Tennessee
- Conditions
- Healthy, Chronic Stable Illness
- Interventions
- casirivimab+imdevimab, Moderna mRNA-1273 vaccine
- Drug · Biological
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 295 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Hialeah, Florida + 3 more
- Conditions
- COVID-19
- Interventions
- casirivimab+imdevimab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 1 Minute to 12 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Anaheim, California • Miami, Florida • Stony Brook, New York + 4 more
- Conditions
- Immunocompromised
- Interventions
- casirivimab+imdevimab, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 48 more
- Conditions
- COVID-19
- Interventions
- casirivimab+imdevimab combination therapy
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 10,078 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 102
- States / cities
- Mesa, Arizona • Tucson, Arizona • Canoga Park, California + 71 more
- Conditions
- COVID-19
- Interventions
- REGN10933+REGN10987 combination therapy, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 96
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 70 more